Clinical Trial Detail

NCT ID NCT03095781
Title Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

pancreatic adenocarcinoma

small intestine adenocarcinoma

hepatocellular carcinoma

colorectal adenocarcinoma

gastroesophageal junction adenocarcinoma

cholangiocarcinoma

gastric adenocarcinoma

Therapies

Pembrolizumab + XL888

Age Groups: adult senior

No variant requirements are available.